Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that young women with low prolactin levels may face higher cardiometabolic risk, and reducing cabergoline dosage reversed related metabolic disturbances.

This study found that topical patidegib gel significantly shrank basal cell carcinomas in Gorlin syndrome patients without causing the systemic side effects common with oral hedgehog inhibitors.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This paper discusses the complex relationship between polycystic ovary syndrome (PCOS) and hyperprolactinemia, noting a decrease in prolactin levels following bromocriptine treatment, but reports no new clinical findings.

This study observed that over 90% of patients undergoing paclitaxel and platinum chemotherapy for certain gynecological cancers experienced significant, yet reversible, alopecia by the end of treatment.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.

In this study, baricitinib treatment for severe alopecia areata was well tolerated, with minor metabolic changes and PLR emerging as a sensitive marker of treatment response.

This study found that six months of combined estrogen-progestin pill therapy led to a significant reduction in serum AMH levels and improvement in hyperandrogenic symptoms among women with PCOS.

This study suggests bicalutamide may be effective in reducing hair loss severity in female pattern hair loss, particularly when other antiandrogen therapies are less effective due to hyperandrogenic conditions.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This review explores current and emerging treatments for polycystic ovary syndrome, focusing on managing hyperandrogenism and cardiometabolic risk, but reports no new clinical results.

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

This study found that adding pioglitazone to either spironolactone or metformin improved metabolic parameters and insulin resistance in women with PCOS, despite an increase in BMI.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study identified procyanidin B2 and leucopelargonidin from Saraca asoca as potential inhibitors in PCOS by showing high binding energy scores against key enzymes involved in estrogen and testosterone biosynthesis.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This study found that the retinoid LGD1069 suppressed mammary tumorigenesis in a mouse model without observable toxicity, while TTNPB showed modest effects but was associated with significant toxicity.

This study found that antiandrogenic pretreatment with combined oral contraceptives did not improve ovulation and pregnancy outcomes compared to direct letrozole induction in women with PCOS.

This study reported that both phlebotomy and oral contraceptive pills with cyproterone acetate effectively improved insulin resistance and androgenic profiles in women with PCOS, but OCs had more impact on regularizing menstrual cycles.

This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study assessed vitamin E and a combined oral contraceptive's impact on continuous light-induced PCOS in female rats, finding they reduced testosterone levels and modified oxidative stress, suggesting benefits via melatonin-related pathways.

This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.